Soluble urokinase activator receptor (suPAR) in stem cell mobilization

Blood

Volumn 105, Issue 5, 2005, Pages 1847-1848

  Sloand, Elaine Marie ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; GRANULOCYTE COLONY STIMULATING FACTOR; PLASMINOGEN ACTIVATOR; STEM CELL FACTOR; UROKINASE; UROKINASE RECEPTOR; CELL SURFACE RECEPTOR; PLASMINOGEN ACTIVATOR, UROKINASE RECEPTORS;

CELL ADHESION; CELL SURFACE; CHEMOTAXIS; DOWN REGULATION; FIBRINOLYSIS; HUMAN; LEUKAPHERESIS; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; REVIEW; STEM CELL MOBILIZATION; DRUG EFFECT; NOTE; PHYSIOLOGY; SOLUBILITY;

CELL ADHESION; CHEMOTAXIS; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HUMANS; RECEPTORS, CELL SURFACE; SOLUBILITY;

EID: 14944349469     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2004-12-4766     Document Type: Review

References (7)

1. Moncada V, Bolan C, Yau YY, Leitman SF. Analysis of PBPC cell yields during large-volume leukapheresis of subjects with a pour mobilization response to filgrastim. Transfusion. 2003;43:495-501.
2. Plesner T, Behrendt N, Ploug M. Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor, uPAR. Stem Cells. 1997;15:398-408.
3. Hoyer-Hasen G, Behrendt N. Ploug M, Dano K, Preissner KT. The intact urokinase receptor is required for efficient vitronectin binding: receptor cleavage prevents liarand interaction. FEBS Lett. 1997;420:79-85.
4. Pedersen TL, Yong K, Pedersen JO, Hansen NE. Impaired migration in vitro of neutrophils from patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol. 1996;95:45-51.
5. Wilhelm OG, Wilhelm S, Escott GM et al. Cellular glycosylphosphatidylinositol-specific phospholipase Dregulates urokinase receptor shedding and cell surface expression. J Cell Physiol. 1999;180:225-235.
6. Nijziel MR, Van OR, Hellenbrand D et al. The prognostic value of the soluble urokinase-type plasminogen activator receptor (s-uPAR) in plasma of breast cancer patients with and without metastatic disease. J Thromb Haemost. 2003;1:982-986.
7. Ninomiya H, Hasegawa Y, Nagasawa T, Abe T. Excess soluble urokinase-type plasminogen activator receptor in the plasma of patients with paroxysmal nocturnal hemoglobinuria inhibits cell-associated fibrinolytic activity. Int J Hematol. 1997;65:285-291.